RELATIVE CHANGES IN HEPATITIS-C VIRUS RNA TITRE AND SERUM ALT LEVELS BEFORE, DURING AND AFTER TREATMENT WITH INTERFERON AND RIBAVIRIN

WAQAR AZIM,1 MARIA MUSHTAQ GILL,1 SAAD AZIM2** AND JAVAID USMAN1
Departments of1Pathology and 2Medicine, Army Medical College, National University of Sciences and Technology, Islamabad. **Armed Forces Postgraduate Medical Institute (AFPGMI), Rawalpindi – Pakistan

ABSTRACT
Hepatitis C is commonly treated with Interferon and Ribavirin combination therapy. The aim of this study was to find the relative change in the Hepatitis C virus (HCV) RNA titre and serum alanine aminotransferase (ALT) levels before, during and after completion of treatment with Interferon (IFN) and Ribavirin therapy in HCV positive patients.

Patients and Methods: This cross sectional descriptive study was conducted from May 2010 to August 2010. Seventy hepatitis C patients reporting to the Laboratory of Army Medical College, Rawalpindi, were included in the study. Blood samples were first subjected to centrifugation and stored at –20°C till tested. HCV RNA titre was determined by Real Time PCR while ALT estimation on serum samples was done on Selectra-E by kinetic method. The age, gender and treatment status of the patients was also recorded.

Result: In a total of 70 patients, 30% were females while 70% were males. The mean age of patients was 38 ± 11 yrs. On applying, analysis of variance (ANOVA), we found that the change in serum ALT level was significant (F = 6.044 and p = 0.004) while it was not significant in case of HCV RNA (F = 1.93 and p = 0.153) treatment with Inj. IFN and Ribavirin.

Conclusion: There is a definite decreasing trend in the serum ALT levels while no definite relationship of the HCV RNA level to the treatment with combination therapy with IFN and Ribavirin.

Key Words: Hepatitis C, Interferon, Polymerase Chain Reaction.

INTRODUCTION
HCV is a single stranded, linear RNA virus, belonging to the family Flaviviridae. HCV or non-A, non-B hepatitis was first recognized in 1975.1 It is the major cause of post transfusion hepatitis i.e in 80 – 95% cases.1 There are at least six different genotypes, with a varying prevalence in different parts of the world.1

The response to treatment depends not only on the genotype but also on the viral load.3,4 Those with lower load respond are better than those with higher load.3 In HCV genotype – 2 and 3, often requiring short course with combination therapy, the sustained response rate is 65% while in genotype – 1 which often requires a longer treatment regimen, it is 30%.3,4 The results of interferon monotherapy are not satisfactory and those with combination therapy are about 25 – 60% and only about 41 – 48% remain HCV negative in the subsequent 6 months period after treatment.5–8 The option of high doses of Pegylated (PEG) – IFN should be especially considered in situations in which short – course treatment regimens are used or in cases of infection with genotype 1.1

Normal serum ALT levels are observed in approximately 25 – 30% of people with chronic HCV infections, called healthy carriers.9 The aim of this study was to find out the relative change in the HCV RNA titre and serum ALT levels before, during and after completion of treatment with interferon therapy in HCV positive patients.

PATIENTS AND METHODS
This cross sectional and descriptive study was conducted in the Department of Pathology, Army Medical College Rawalpindi, National University of Sciences and Technology, Islamabad, from May 2010 to August 2010. Seventy, non-duplicate patients were included in the study.

Routine blood samples were first subjected to centrifugation and then stored at –20°C till tested. The RNA extraction was done using the Ribo virus
(HCV Real – TM Qual) kit of Sacace Biotechnologies, as per guidelines. This was followed by annealing, amplification and finally, Hepatitis – C RNA detection was done by Real Time PCR, running for forty cycles. ALT estimation of the HCV RNA positive serum samples was done on automated analyzer Selectra – E by kinetic method while maintaining a strict internal and external quality control. The age, gender and treatment status of the patients was also recorded.

The results were interpreted using Statistical Package for the Social Sciences (SPSS) version 17. The p-values equivalent 0.05 or < 0.05 were considered statistically significant.

RESULTS
Among a total of 94 patients, 27(30%) were females while 63 (70%) were males as shown in the Fig. 1. The average age of patients was 38 ± 11 years. The mean values of serum ALT and HCV RNA titres of the patients who had not yet started their treatment those taking combination therapy with Inj. interferon, 3MU three times a week, subcutaneously and capsule Ribavirin 600 mg orally, and those who had completed their course of treatment are summarised in table 1. On applying, analysis of variance (ANOVA), we found that the change in serum ALT level was significant (F = 6.044 and p = 0.004) while it was not significant in case of HCV RNA (F=1.93 and p = 0.153), during treatment with IFN and Ribavirin.

On the whole, there was no correlation of the age of the patients with the HCV RNA titre (r = 0.135) or the serum ALT level (r = 0.037). Moreover, no correlation was found between the HCV RNA titre and serum ALT levels (r = 0.008) in the patients who had not started their treatment while a statistically significant correlation was found in the patients who had completed their treatment with IFN (correlation coefficient = 0.596, p = 0.004).

DISCUSSION
In the present study, we found that during treatment with Inj. Interferon and ribavirin, the serum ALT levels tend to decline significantly from before treatment to after completion of treatment, while we found no significant decreasing trend in the HCV RNA titre.

A study conducted by Anand et al, no correlation was found between HCV RNA levels and age of the patients (r = 0.181). Moreover, no correlation was observed between serum HCV RNA levels and the severity of liver disease, as judged by the value of ALT (r = 0.06) level. Similarly in another study reported in 2005, Garson et al found a variable response of the patients to the interferon therapy, in terms of HCV RNA titre and ALT levels. In their study, HCV viraemia became undetectable within 1 month of commencing interferon in three of the five patients whose serum ALT levels decreased to normal on therapy. In the remaining two patients, viraemia levels declined more slowly, becoming undetectable after a period of several months. Recurrence of viraemia during therapy was observed in two cases. The one patient whose serum ALT levels remained elevated throughout therapy, showed no decline in viraemia.

In another study conducted by Kakumu et al, out of a total of forty three hepatitis C patients, sixteen subjects showed sustained loss of viraemia with normalised ALT values. The other 27 subjects were non-responders (NR), who did not show a loss of viraemia. Lee et al, in their study, conducted in 2001, found that serum ALT levels were not positively correlated with HCV RNA titers. Similarly, in a study conducted by Ghany et al, a significant correlation was found between serum HCV RNA and ALT levels in the patients who received IFN therapy, but no correlation was observed in the untreated patients.

From the above discussion, it is concluded that serum ALT level has a linear response to the combi-

**Table 1:** Mean values of the HCV RNA and serum ALT levels in the groups of before during and after treatment with IFN and Ribavirin.
ned treatment with IFN and ribavirin but HCV RNA has no linear relationship with this combination treatment. We recommend a large scale study, with complete follow up of the patients along with their genotyping to see the response of HCV RNA and ALT levels to the treatment regimen with IFN and ribavirin.

ACKNOWLEDGEMENT
We are thankful to the administration of Army Medical College, Rawalpindi and National University of Sciences and Technology, Islamabad – Pakistan.

REFERENCES